Gene Silencing Market Outlook 2025–2032

[Amisha]

As of 2024, the global Gene Silencing market is valued at approximately USD 4.63 billion and is projected to reach around USD 9.09 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 7.75% during the forecast period . This growth is attributed to the increasing prevalence of genetic disorders, advancements in gene silencing technologies, and rising investments in research and development.

 
Report Sample includes:
- Table of Contents
- List of Tables & Figures
- Charts
- Research Methodology


Get FREE Sample of this Report at https://www.intelmarketresearch.com/download-free-sample/813/global-gene-silencing-2025-2032

Gene silencing refers to the regulation of gene expression in a cell to prevent the expression of a specific gene. This process can occur during transcription, post-transcription, or meiosis, and is utilized in research and therapeutic applications. Techniques such as RNA interference (RNAi), antisense oligonucleotides (ASOs), and CRISPR-based systems are employed to silence genes, offering potential treatments for various diseases, including cancer, neurological disorders, and genetic conditions.

Competitor Analysis (in brief)

The gene silencing market is characterized by the presence of several key players focusing on product innovation and strategic collaborations. Major companies include:

• Alnylam Pharmaceuticals (USA): A leader in RNAi therapeutics.
• Arrowhead Pharmaceuticals (USA): Develops RNAi-based therapies for various diseases.
• Dicerna Pharmaceuticals (USA): Focuses on RNAi therapeutics.
• Ionis Pharmaceuticals (USA): Specializes in antisense therapies
• Benitec Biopharma (Australia): Develops gene-silencing therapies using DNA-directed RNA interference (ddRNAi) technology .
• Silence Therapeutics (UK): Focuses on RNAi therapeutics.
• OliX Pharmaceuticals (South Korea): Develops RNAi-based therapeutics.
• Arcturus Therapeutics (USA): Specializes in RNA medicines.
• RXi Pharmaceuticals (USA): Develops RNAi-based therapeutics.

Recent Developmnet

In February 2025, Arrowhead Pharmaceuticals, Inc. commemorated Rare Disease Day by expanding its ‘We’ll Get There Soon’ campaign, which was originally launched for healthcare providers in November 2024. This phase includes the introduction of a dedicated educational website, www.LowerMyTGs.com, along with the Spotlight on FCS white paper. These resources provide essential support for patients with Familial Chylomicronemia Syndrome (FCS), an ultra-rare inherited disorder that seriously impairs the body's ability to metabolize triglycerides. This leads to perilously high triglyceride (TG) levels—usually over 880 mg/dL—and strongly raises the risk of life-threatening illness, including acute pancreatitis. Due to this risk, professional guidelines suggest maintaining triglyceride levels below 500 mg/dL.

In May 2023, Novartis purchased a gene therapy candidate from Avrobio, which was facing financial challenges. Novartis made a superb upfront payment of $87.5 million for the clinical-stage asset with no conditions attached for later payments. The deal came with AVR-RD-04, a hematopoietic stem cell gene therapy program under investigation for the treatment of the rare genetic disorder cystinosis.

Global Gene Silencing: Market Segmentation Analysis

This report provides a deep insight into the global Gene Silencing market, covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and assessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Gene Silencing. This report introduces in detail the market share, market performance, product situation, operation situation, etc., of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Gene Silencing in any manner.

Get FREE Sample of this Report at https://www.intelmarketresearch.com/download-free-sample/813/global-gene-silencing-2025-2032


Market Segmentation (by Application)
• Cancer Treatment
• Drug Discovery and Development
• Agricultural Application
• Therapeutics Manufacturing
• Other

Market Segmentation (by Gene Silencing Method )

• RNA Interference (RNAi)
• Antisense Oligonucleotides (ASOs)
• CRISPR/Cas9-Based Gene Silencing
• Others

Market Segmentation (by End Use)

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospitals
• Clinics
• Others

Market Segmentation (by Type)

• Transcriptional
• Post-transcriptional

Key Company

• Alnylam Pharmaceuticals
• Benitec Biopharma
• Arrowhead Pharmaceuticals
• Merck Group
• Eli Lilly (Dicerna Pharmaceuticals)
• Monsanto (Bayer AG)
• RXi Pharmaceuticals
• Silence Therapeutics plc
• Idera Pharmaceuticals


FAQ Section

1. What is the current market size of the Gene Silencing market?

As of 2024, the global Gene Silencing market is valued at approximately USD 4.63 billion and is projected to reach around USD 9.09 billion by 2034 .

2. Which are the key companies operating in the Gene Silencing market?

Major players include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Ionis Pharmaceuticals, Benitec Biopharma, Silence Therapeutics, OliX Pharmaceuticals, Arcturus Therapeutics, and RXi Pharmaceuticals.

3. What are the key growth drivers in the Gene Silencing market?

Key drivers include advancements in gene silencing technologies, rising prevalence of genetic disorders, expanding applications in neurological disorders, and increasing investments in research and development.

4. Which regions dominate the Gene Silencing market?

North America holds the largest market share, followed by Europe and the Asia-Pacific region, which is expected to witness the fastest growth.

5. What are the emerging trends in the Gene Silencing market?

Emerging trends include the development of RNA-based therapeutics, integration of gene silencing in personalized medicine, and advancements in delivery mechanisms for gene silencing agents


Get the Complete Report & TOC at https://www.intelmarketresearch.com/life-sciences/813/global-gene-silencing-2025-2032

CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: [phone]
Email: [e-mail]

Follow Us On linkedin :- https://www.linkedin.com/company/intelsight-research/

About intel market research :

Established ourselves in the year 2015, Intel Market Reports is a popular market research company that provides an in-depth quantified market research report. The Purpose is to deliver effective and fruit-bearing market research reports. Our portfolio includes the list of 30+ companies belonging to the Fortune 500 list. We have achieved this milestone in less than half a decade.